EGFR negative

The prognostic nomogram showed promising prediction efficacy and is expected to predict the prognosis of "driver-gene-negative" LUAD. The easy-to-use nomogram and the enriched pathways can help clinical decision-making, guide follow-up planning, and develop new therapeutic targets.

P2, N=41, Recruiting, Tianjin Medical University Cancer Institute and Hospital

EGFR amplification was frequent in OSCC, and CDKN2A deletion was prevalent in OED, supporting their use as molecular markers for differential diagnoses. FISH for EGFR/CDKN2A and HRAS IHC can stratify OSCC by diagnosis and prognosis, enabling practical molecular subclassification, including EGFR-negative cases.

However, there is concern that overall survival might be shortened if CATs develop. Therefore, the possibility of developing CATs in EGFR-positive NSCLC patients must be addressed.

Never and light smokers with stage IV NSCLC displayed distinct features. The high prevalence of actionable EGFR alterations underscores the importance of comprehensive molecular testing. Region-specific data should inform precision oncology strategies and the design of prospective trials targeting non-traditional risk groups.

We estimated that 8602 patients with newly diagnosed esophageal cancers would be eligible for adjuvant nivolumab...Among NSCLC patients who may undergo resection and qualify for adjuvant therapy, 70,602 patients are anticipated to be epidermal growth factor receptor-negative and treated with adjuvant atezolizumab or pembrolizumab...The cost to treat 1 patient with adjuvant osimertinib was $556,000, with an incident cohort cost of $8 billion...Immune and targeted therapy in operable thoracic patients is associated with a significant cost burden. Studies are needed to assess cost-effectiveness to ensure optimal resource allocation and improve patient outcomes.

Higher CTC signature ITH was associated with increased Oncotype DX risk and higher overall grade. These findings highlight the value of our CTC signature in disease progression and the role of ITH on recurrence risk.

Gamma-camera imaging confirmed that [123I]I-(HE)3-E01-PIB demonstrated a higher imaging contrast in preclinical models than [99mTc]Tc-(HE)3-E01. In conclusion, DARPin (HE)3-E01 labeled using a non-residualizing [123I]I-para-iodobenzoate (PIB) label is the preferred radiotracer for in vivo imaging of EGFR expression in cancer.

Enhertu represents a promising treatment option for HER2-mutant metastatic lung cancer with recurrent brain metastasis. This case highlights the potential of Enhertu in overcoming treatment resistance in complex metastatic settings, warranting further investigation in broader clinical settings.

P2, N=62, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University

P2, N=69, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University

P=N/A, N=424, Recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital | Not yet recruiting --> Recruiting